Erick Hernandez, MD
Pediatric Gastroenterology · Miami, FLNPI 1609803261
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.6%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Travere Therapeutics, Inc. at 60.0% of the total. Reporting peaked in 2019 at $4,356 and has fallen 76.2% since, to $1,037 in 2025.
Across 221 payments — averaging $54.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$7K
- Johnson & Johnson$731
- AbbVie$701
- Sanofi$508
- Takeda Pharmaceuticals U.S.A., Inc.$492
- Janssen Scientific Affairs, LLC$311
- plus $2K from 22 others
What the payments were for
- Consulting fees$6,10051%
- Speaking & faculty fees$7506%
- Food & beverage$4,98741%
- Education$2182%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 37 | $7,232 |
| Johnson & Johnson | 41 | $731 |
| AbbVie | 34 | $701 |
| Sanofi | 17 | $508 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $492 |
| Janssen Scientific Affairs, LLC | 4 | $311 |
| Albireo Pharma, Inc. | 3 | $260 |
| Mirum Pharmaceuticals, Inc. | 6 | $253 |
| Ipsen Biopharmaceuticals, Inc | 9 | $223 |
| QOL Medical, LLC | 15 | $222 |
| Regeneron Healthcare Solutions, Inc. | 8 | $196 |
| Medtronic | 1 | $150 |
| Intrabio Inc | 2 | $146 |
| TG Therapeutics, Inc. | 1 | $116 |
| AstraZeneca | 2 | $84 |
| Nestle Healthcare Nutrition Inc. | 4 | $80 |
| Amgen | 4 | $75 |
| Orphalan Inc | 3 | $68 |
| Organon | 3 | $47 |
| Eton Pharmaceuticals, Inc. | 1 | $24 |
| Mauna Kea Technologies, Inc. | 1 | $23 |
| Celltrion USA Inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Amryt Pharma Holdings Ltd | 1 | $18 |
| Aimmune Therapeutics, Inc. | 1 | $14 |
| Phadia US Inc. | 1 | $14 |
| Olympus America Inc. | 1 | $14 |
| Laborie Medical Technologies Corp. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,055 in reported general payments places this provider in the 85th percentile of 128 pediatric gastroenterology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Famotidine | 13 | $6,240 |
Paid to pharmacies, not to this prescriber.
Other pediatric gastroenterology in Miami
- Alisa Muniz CrimMiami$50K
- Miguel SapsMiami$9K
- Jennifer GarciaMiami$6K
- Lina FelipezMiami$5K
- Richard ArboledaMiami$5K
- Luis Caicedo OquendoMiami$5K
- Jesse Reeves-GarciaMiami$5K
- Oscar Loret de MolaMiami$4K
- Laura IrastorzaMiami$4K
- Robert GomaraMiami$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.